Tectonic Therapeutics TECX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31.4%— | -37.8%— | -32.2%— | -29.3%— | —— | |
| Return on assets | -29.7%-0.9pp | -35.8%+24.5pp | -30.2%+8.1pp | -27%+1.0pp | -28.8%+20.9pp | |
| Liquidity | ||||||
| Current ratio | 18.5×-4.4× | 26.6×+14.0× | 29.2×+19.8× | 25.6×+18.4× | 22.9×-3.3× | |
| Quick ratio | 18.5×-4.4× | 26.6×+14.0× | 29.2×+19.8× | 25.6×+18.4× | 22.9×-3.3× | |
| Cash ratio | 18.3×-4.4× | 26.3×+14.0× | 28.8×+19.5× | 25.3×+18.2× | 22.7×+17.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -1,824.3×-1,157× | -1,333.9×-787× | -1,048.1×-596× | -884×-544× | -666.8×-361× | |
| Per Share | ||||||
| Book value per share | $12.28-30.0% | $13.72-17.3% | $14.30+40.0% | $15.19-73.3% | $17.55+124% | |
| Valuation | ||||||
| Market capitalization | $585.51M+58.3% | $390.42M-42.7% | $293.59M— | $376.62M— | $330.52M— | |
| Enterprise value | $353.51M+438% | $138.24M-74.5% | $25.32M— | $90.6M— | $26.31M— | |
| Price / book | 2.5×+1.3× | 1.6×-3.3× | 1.1×— | 1.3×— | 1.1×— | |
| Free cash flow yield | -11.2%+5.8pp | -15.4%-6.7pp | -21.3%— | -17.1%— | -19.1%— | |
| Earnings yield | -14.3%+1.6pp | -19%-10.5pp | -22.9%— | -17.5%— | -17.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tectonic Therapeutics's ratios come from?
- Every ratio is computed from Tectonic Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.